Article
In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden.
Cytotherapy - 1 Apr 2021
Ferrari Valentina, Tarke Alison, Fields Hannah, Ferrari Luca, Conley Trevor, Ferrari Franco, Koşaloğlu-Yalçın Zeynep, Sette Alessandro, Peters Bjoern, McCarthy Colin L, Bashey Asad, Tzachanis Dimitrios, Ball Edward D, Tanaka Tiffany N, Bejar Rafael, Lane Thomas A, Vitiello Antonella
Abstract excerpt
Therapies that utilize immune checkpoint inhibition work by leveraging mutation-derived neoantigens and have shown greater clinical efficacy in tumors with higher mutational burden. Whether tumors with a low mutational burden are susceptible to neoantigen-targeted therapy has not been fully addressed. To examine the feasibility of neoantigen-specific adoptive T-cell therapy, the authors studied the T-cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.